Is ASPCF or JNJ a better dividend investment in 2026?

ASPCF currently yields 909.59% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: ASPCF offers higher current income.

What is the dividend yield difference between ASPCF and JNJ?

ASPCF has a forward dividend yield of 909.59% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 906.23 percentage points.

Home › Compare › ASPCF vs JNJ

ASPCF vs JNJ: Dividend Comparison 2026

ASPCF yields 909.59% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ASPCF wins by $8291497.75M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ASPCF

● Live price

909.59%

Share price

$0.22

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8291497.77M

Annual income

$6,817,159,983,407.13

Full ASPCF calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — ASPCF vs JNJ

📍 ASPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ASPCF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ASPCF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ASPCF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASPCF

Annual income on $10K today (after 15% tax)

$77,314.90/yr

After 10yr DRIP, annual income (after tax)

$5,794,585,985,896.06/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, ASPCF beats the other by $5,794,585,985,192.45/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASPCF + JNJ for your $10,000?

ASPCF: 50%JNJ: 50%

100% JNJ50/50100% ASPCF

Portfolio after 10yr

$4145748.89M

Annual income

$3,408,579,992,117.45/yr

Blended yield

82.22%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ASPCF

No analyst data

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASPCF buys

JNJ buys

No recent congressional trades found for ASPCF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricASPCFJNJ

Forward yield	909.59% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$8291497.77M ✓	$20.0K
Annual income after 10y	$6,817,159,983,407.13 ✓	$827.78
Total dividends collected	$8177275.77M ✓	$5.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ASPCF vs JNJ ($10,000, DRIP)

Year	ASPCF Portfolio	ASPCF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$101,659	$90,958.70	$10,676	$355.77	+$91.0K → ASPCF
2	$972,957	$864,181.69	$11,407	$389.39	+$961.5K → ASPCF
3	$8,770,897	$7,729,833.49	$12,198	$426.53	+$8.76M → ASPCF
4	$74,508,241	$65,123,381.48	$13,056	$467.62	+$74.50M → ASPCF
5	$596,751,110	$517,027,292.00	$13,987	$513.12	+$596.74M → ASPCF
6	$4,508,591,853	$3,870,068,165.34	$14,998	$563.56	+$4508.58M → ASPCF
7	$32,150,599,702	$27,326,406,419.03	$16,098	$619.52	+$32150.58M → ASPCF
8	$216,516,638,004	$182,115,496,323.36	$17,295	$681.69	+$216516.62M → ASPCF
9	$1,377,885,778,910	$1,146,212,976,244.92	$18,599	$750.82	+$1377885.76M → ASPCF
10	$8,291,497,766,840	$6,817,159,983,407.13	$20,022	$827.78	+$8291497.75M → ASPCF

ASPCF vs JNJ: Complete Analysis 2026

ASPCF — Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Full ASPCF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this ASPCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASPCF vs SCHD ASPCF vs JEPI ASPCF vs O ASPCF vs KO ASPCF vs MAIN ASPCF vs ABBV ASPCF vs MRK ASPCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.